{
    "hands_on_practices": [
        {
            "introduction": "A drug's clinical success depends not only on its interaction with a biological target but also on its ability to travel from a dosage form into the bloodstream. This exercise challenges you to think like a formulation scientist by applying the Biopharmaceutics Classification System (BCS), a foundational framework that links a drug's intrinsic solubility and permeability to its potential in vivo performance. By analyzing physicochemical data, you will learn to classify a compound and devise a rational formulation strategy to achieve a desired pharmacokinetic profile, bridging the gap between the molecule and the medicine .",
            "id": "4591720",
            "problem": "A development team must decide a clinical formulation for an oral small-molecule candidate, Compound X, using biopharmaceutic principles. The highest proposed clinical dose per administration is $M = 200\\,\\mathrm{mg}$. Equilibrium solubility was measured after $24\\,\\mathrm{h}$ across gastric and proximal intestinal pH values: pH $1$: $12\\,\\mathrm{mg/mL}$, pH $3$: $3\\,\\mathrm{mg/mL}$, pH $5$: $0.5\\,\\mathrm{mg/mL}$, pH $6$: $0.25\\,\\mathrm{mg/mL}$. The apparent permeability coefficient $P_{\\mathrm{app}}$ across the human colorectal adenocarcinoma (Caco-2) cell monolayer is $14 \\times 10^{-6}\\,\\mathrm{cm/s}$ with an efflux ratio $ER = 1.2$. The desired clinical targets in healthy adults after a single oral dose $M$ are peak plasma concentration $C_{\\max} = 5\\,\\mathrm{mg/L}$ and time to peak $T_{\\max} = 1.0\\,\\mathrm{h}$. Assume the regulatory dissolution medium volume benchmark is $V = 250\\,\\mathrm{mL}$ and that oral elimination follows one-compartment kinetics with first-order elimination, with half-life $t_{1/2} = 3.5\\,\\mathrm{h}$.\n\nUsing the Biopharmaceutics Classification System (BCS; Biopharmaceutics Classification System) definitions for high versus low solubility and permeability, and first principles of dissolution and absorption, select the option that most appropriately classifies Compound X and recommends a formulation strategy most likely to achieve the target $C_{\\max}$ and $T_{\\max}$.\n\nA. BCS Class II; develop an immediate-release amorphous solid dispersion with a hydrophilic polymer and surfactant to increase apparent solubility and the dissolution rate, thereby increasing $k_a$ relative to $k_e$.\n\nB. BCS Class III; focus on permeability enhancement (e.g., bile salts, prodrug) and controlled-release to slow input and reduce $C_{\\max}$.\n\nC. BCS Class II; use an enteric-coated formulation to delay release until pH $6$ and maintain large particle size to limit gastric dissolution.\n\nD. BCS Class I; produce a simple film-coated tablet with no solubility enhancement and target extended-release to flatten the profile.",
            "solution": "The problem requires a two-part analysis: first, classifying Compound X according to the Biopharmaceutics Classification System (BCS), and second, selecting a formulation strategy that aligns with this classification and the desired pharmacokinetic targets.\n\n**Part 1: BCS Classification**\n\nThe BCS classifies drugs based on their aqueous solubility and intestinal permeability.\n\n1.  **Solubility Analysis**:\n    *   According to BCS guidelines, a drug is considered \"highly soluble\" if its highest proposed clinical dose is soluble in $250\\,\\mathrm{mL}$ or less of aqueous media over the physiological pH range (typically pH 1 to 6.8).\n    *   The highest dose is $M = 200\\,\\mathrm{mg}$. The benchmark volume is $V = 250\\,\\mathrm{mL}$.\n    *   To be highly soluble, the required solubility ($S_{\\text{req}}$) is $M/V = 200\\,\\mathrm{mg} / 250\\,\\mathrm{mL} = 0.8\\,\\mathrm{mg/mL}$.\n    *   We check the compound's solubility against this threshold at all provided pH values:\n        *   At pH 1: $12\\,\\mathrm{mg/mL} > 0.8\\,\\mathrm{mg/mL}$ (soluble)\n        *   At pH 3: $3\\,\\mathrm{mg/mL} > 0.8\\,\\mathrm{mg/mL}$ (soluble)\n        *   At pH 5: $0.5\\,\\mathrm{mg/mL}  0.8\\,\\mathrm{mg/mL}$ (**not soluble**)\n        *   At pH 6: $0.25\\,\\mathrm{mg/mL}  0.8\\,\\mathrm{mg/mL}$ (**not soluble**)\n    *   Since the compound fails to meet the solubility criterion in the intestinal pH range (pH 5 and 6), it is classified as **low solubility**.\n\n2.  **Permeability Analysis**:\n    *   A drug is considered \"highly permeable\" if the extent of human absorption is high ($\\ge 85\\%$). This is often predicted using in vitro models like Caco-2 cell monolayers.\n    *   A common threshold for high permeability in the Caco-2 assay is a $P_{\\mathrm{app}} \\ge 10 \\times 10^{-6}\\,\\mathrm{cm/s}$.\n    *   The measured $P_{\\mathrm{app}}$ for Compound X is $14 \\times 10^{-6}\\,\\mathrm{cm/s}$, which is greater than the threshold.\n    *   The efflux ratio ($ER$) of $1.2$ is low (close to 1), suggesting that active efflux mechanisms are not significantly limiting the drug's absorption.\n    *   Therefore, the compound is classified as **high permeability**.\n\n**Conclusion of BCS Classification**: With low solubility and high permeability, Compound X is a **BCS Class II** drug.\n\n**Part 2: Formulation Strategy**\n\nFor BCS Class II drugs, oral absorption is limited by the rate of dissolution. The pharmacokinetic target is a very rapid onset, indicated by $T_{\\max} = 1.0\\,\\mathrm{h}$. A short $T_{\\max}$ implies that the absorption rate constant ($k_a$) must be significantly greater than the elimination rate constant ($k_e$). The required strategy is therefore to maximize the dissolution rate.\n\nLet's evaluate the options based on this analysis:\n\n*   **A. BCS Class II; develop an immediate-release amorphous solid dispersion with a hydrophilic polymer and surfactant to increase apparent solubility and the dissolution rate, thereby increasing $k_a$ relative to $k_e$.**\n    *   This option correctly identifies the BCS class. An amorphous solid dispersion (ASD) is a state-of-the-art enabling technology specifically designed to increase the dissolution rate and apparent solubility of poorly soluble compounds. This directly increases $k_a$, which is necessary to achieve a short $T_{\\max}$. This strategy is perfectly aligned with the data and the clinical goal.\n\n*   **B. BCS Class III; focus on permeability enhancement... and controlled-release...**\n    *   This is incorrect. The BCS class is wrong, permeability is already high, and controlled-release would slow absorption, contradicting the target $T_{\\max}$.\n\n*   **C. BCS Class II; use an enteric-coated formulation to delay release until pH 6...**\n    *   While the BCS class is correct, the strategy is counterproductive. Releasing the drug at pH 6, where its solubility is the lowest, and using large particles would minimize, not maximize, the dissolution rate.\n\n*   **D. BCS Class I; produce a simple film-coated tablet with no solubility enhancement...**\n    *   This is incorrect. The BCS class is wrong, and failing to use a solubility enhancement strategy for a dissolution-rate-limited drug would lead to poor and variable bioavailability, failing to meet the PK targets.\n\n**Final Conclusion**: Option A is the only choice that correctly classifies the drug and proposes a scientifically sound formulation strategy to meet the specified pharmacokinetic objectives.",
            "answer": "$$\\boxed{A}$$"
        },
        {
            "introduction": "After designing a promising oral formulation, its clinical performance must be rigorously quantified. This practice guides you through the fundamental derivation and calculation of absolute bioavailability ($F_{\\text{abs}}$), a cornerstone metric in early clinical development. By comparing the systemic exposure from an oral dose to that of a direct intravenous (IV) administration, you will master the principles behind determining the precise fraction of a drug that successfully enters circulation, a critical step in understanding and optimizing oral drug delivery .",
            "id": "4591723",
            "problem": "A semi-synthetic lead derived from a marine natural product is advanced into first-in-human studies. In a crossover design with healthy volunteers, both an extravascular oral dose and an intravenous dose are administered on separate periods with sufficient washout. Plasma concentrations are assayed using the same validated method in both periods, with rich sampling to allow reliable estimation of the area under the concentration–time curve from time zero extrapolated to infinity, denoted $\\mathrm{AUC}_{0-\\infty}$. Assume linear, time-invariant pharmacokinetics with route-independent clearance, negligible saturable first-pass extraction within the studied dose range, and that intravenous bioavailability equals $1$ by definition.\n\nTasks:\n1. Define in words the concepts of absolute bioavailability and relative bioavailability, making clear the reference administrations involved in each definition.\n2. Starting only from fundamental pharmacokinetic definitions (for example, that clearance is the proportionality between elimination rate and concentration, and that exposure integrates concentration over time), derive an expression for the absolute bioavailability $F_{\\text{abs}}$ in terms of $\\mathrm{AUC}_{0-\\infty}$ and administered dose for an extravascular administration compared to an intravenous administration under the assumptions stated. Your derivation must eliminate any unknown system parameters not directly observed in the study design.\n3. In the study, the oral extravascular dose was $D_{\\text{EV}} = 100\\,\\mathrm{mg}$ with $\\mathrm{AUC}_{0-\\infty,\\ \\text{EV}} = 12.0\\,\\mathrm{mg\\cdot h/L}$, and the intravenous dose was $D_{\\text{IV}} = 20.0\\,\\mathrm{mg}$ with $\\mathrm{AUC}_{0-\\infty,\\ \\text{IV}} = 8.00\\,\\mathrm{mg\\cdot h/L}$. Using your derived expression, compute the absolute bioavailability $F_{\\text{abs}}$ for the oral dose. Express your final answer as a unitless decimal fraction and round to three significant figures.",
            "solution": "The problem statement has been critically validated and is deemed to be scientifically grounded, well-posed, and objective. It contains a complete and consistent set of givens and assumptions standard to the field of clinical pharmacokinetics, allowing for a rigorous, formal solution. The problem is a valid exercise in applying fundamental principles to derive and compute a key pharmacokinetic parameter.\n\nThe solution is structured in three parts as requested by the problem statement.\n\nTask 1: Definitions of Absolute and Relative Bioavailability\n\nAbsolute bioavailability, denoted as $F_{\\text{abs}}$, is defined as the fraction of an administered dose of a drug that reaches the systemic circulation when administered via an extravascular route (e.g., oral, intramuscular, subcutaneous, transdermal). The reference administration for determining absolute bioavailability is always an intravenous (IV) bolus or infusion of the same drug. The bioavailability of an IV administration is, by definition, unity ($1$) or $100\\%$, as the entire dose is delivered directly into the systemic circulation.\n\nRelative bioavailability, denoted as $F_{\\text{rel}}$, compares the bioavailability of a drug from one formulation (e.g., a new oral tablet) to that of another formulation of the same drug administered by the same or a different extravascular route, which serves as the reference standard (e.g., an established oral solution or a marketed tablet). It is the ratio of the two bioavailabilities. For instance, if formulation A is being compared to a reference formulation B, the relative bioavailability of A is given by $F_{\\text{rel}} = F_A / F_B$. This parameter is crucial in bioequivalence studies.\n\nTask 2: Derivation of the Expression for Absolute Bioavailability\n\nThe derivation begins from the fundamental definition of systemic clearance ($CL$). Clearance is the volume of plasma cleared of drug per unit time, and it serves as the proportionality constant that relates the rate of drug elimination from the body to the plasma drug concentration, $C(t)$.\n$$\n\\text{Rate of elimination}(t) = CL \\cdot C(t)\n$$\nThe total amount of drug eliminated from the body over all time ($t=0$ to $t=\\infty$) is the integral of this rate. Assuming clearance is constant (a cornerstone of linear, time-invariant pharmacokinetics), it can be factored out of the integral.\n$$\n\\text{Total amount eliminated} = \\int_{0}^{\\infty} \\left( CL \\cdot C(t) \\right) dt = CL \\cdot \\int_{0}^{\\infty} C(t) dt\n$$\nThe integral term, $\\int_{0}^{\\infty} C(t) dt$, is by definition the area under the plasma concentration-time curve from time zero extrapolated to infinity, denoted $\\mathrm{AUC}_{0-\\infty}$.\n$$\n\\text{Total amount eliminated} = CL \\cdot \\mathrm{AUC}_{0-\\infty}\n$$\nAccording to the principle of mass balance, over an infinite time horizon, the total amount of drug eliminated must equal the total amount of drug that reached the systemic circulation. Let this bioavailable amount be $A_b$.\n$$\nA_b = CL \\cdot \\mathrm{AUC}_{0-\\infty}\n$$\nThis equation can be rearranged to express clearance:\n$$\nCL = \\frac{A_b}{\\mathrm{AUC}_{0-\\infty}}\n$$\nWe now apply this relationship to the two administration routes described in the problem, intravenous (IV) and extravascular (EV).\n\nFor the intravenous (IV) administration, the dose is $D_{\\text{IV}}$. By definition, an IV dose has an absolute bioavailability of $1$. Therefore, the total amount of drug that reaches the systemic circulation is the entire dose:\n$$\nA_{b, \\text{IV}} = D_{\\text{IV}}\n$$\nThe clearance, determined from the IV data, is therefore:\n$$\nCL = \\frac{D_{\\text{IV}}}{\\mathrm{AUC}_{0-\\infty, \\text{IV}}}\n$$\nFor the extravascular (EV) administration, the dose is $D_{\\text{EV}}$. The fraction of this dose that reaches the systemic circulation is the absolute bioavailability, $F_{\\text{abs}}$. Thus, the bioavailable amount is:\n$$\nA_{b, \\text{EV}} = F_{\\text{abs}} \\cdot D_{\\text{EV}}\n$$\nThe clearance, as determined from the EV data, is:\n$$\nCL = \\frac{A_{b, \\text{EV}}}{\\mathrm{AUC}_{0-\\infty, \\text{EV}}} = \\frac{F_{\\text{abs}} \\cdot D_{\\text{EV}}}{\\mathrm{AUC}_{0-\\infty, \\text{EV}}}\n$$\nThe problem specifies the crucial assumption of \"route-independent clearance\". This means that the clearance of the drug from the body is a systemic property and does not depend on how the drug was administered. Therefore, the clearance value calculated from the IV data must be equal to the clearance value calculated from the EV data. We can equate the two expressions for $CL$. This step is what allows for the elimination of the unknown system parameter $CL$.\n$$\n\\frac{D_{\\text{IV}}}{\\mathrm{AUC}_{0-\\infty, \\text{IV}}} = \\frac{F_{\\text{abs}} \\cdot D_{\\text{EV}}}{\\mathrm{AUC}_{0-\\infty, \\text{EV}}}\n$$\nTo find the expression for absolute bioavailability, $F_{\\text{abs}}$, we algebraically rearrange this equation:\n$$\nF_{\\text{abs}} = \\frac{\\mathrm{AUC}_{0-\\infty, \\text{EV}}}{\\mathrm{AUC}_{0-\\infty, \\text{IV}}} \\cdot \\frac{D_{\\text{IV}}}{D_{\\text{EV}}}\n$$\nThis is the derived expression for absolute bioavailability. It represents the ratio of the dose-normalized areas under the curve for the extravascular and intravenous administrations.\n\nTask 3: Calculation of Absolute Bioavailability\n\nThe derived expression is used with the provided study data to compute the numerical value of $F_{\\text{abs}}$.\nThe given values are:\nExtravascular oral dose: $D_{\\text{EV}} = 100\\,\\mathrm{mg}$\nExtravascular oral AUC: $\\mathrm{AUC}_{0-\\infty, \\text{EV}} = 12.0\\,\\mathrm{mg\\cdot h/L}$\nIntravenous dose: $D_{\\text{IV}} = 20.0\\,\\mathrm{mg}$\nIntravenous AUC: $\\mathrm{AUC}_{0-\\infty, \\text{IV}} = 8.00\\,\\mathrm{mg\\cdot h/L}$\n\nSubstituting these values into the derived formula:\n$$\nF_{\\text{abs}} = \\frac{12.0\\,\\mathrm{mg\\cdot h/L}}{8.00\\,\\mathrm{mg\\cdot h/L}} \\cdot \\frac{20.0\\,\\mathrm{mg}}{100\\,\\mathrm{mg}}\n$$\nThe units $(\\mathrm{mg\\cdot h/L})$ and $(\\mathrm{mg})$ cancel out, rendering $F_{\\text{abs}}$ a unitless fraction, as expected.\n$$\nF_{\\text{abs}} = \\frac{12.0}{8.00} \\cdot \\frac{20.0}{100}\n$$\nPerforming the calculation:\n$$\nF_{\\text{abs}} = 1.50 \\cdot 0.200\n$$\n$$\nF_{\\text{abs}} = 0.300\n$$\nThe input values are all provided to three significant figures. The intermediate results ($1.50$ and $0.200$) and the final result should therefore be expressed with three significant figures. The calculated value is $0.300$. The problem asks for the answer to be rounded to three significant figures, which is already the case.",
            "answer": "$$\n\\boxed{0.300}\n$$"
        },
        {
            "introduction": "The culmination of early drug development is the critical decision of which doses to advance into large-scale, pivotal Phase III trials. This hands-on computational practice introduces you to the modern, quantitative approach of pharmacometrics, which uses mathematical models to simulate clinical trial outcomes. By integrating models for exposure, efficacy ($E_{\\max}$), and safety, you will learn to use Monte Carlo simulation to explore the benefit-risk trade-offs of different dosing regimens and select optimal doses that maximize the probability of a successful trial .",
            "id": "4591706",
            "problem": "You are given a decision problem for Phase III dose selection grounded in foundational pharmacometric principles. You will simulate exposure–response using Monte Carlo methods to approximate expectations, then select two Phase III dose levels that balance efficacy and safety based on formalized criteria. The base assumptions and models are as follows.\n\nFundamental base:\n- Linear pharmacokinetics: exposure is proportional to dose divided by clearance, so for dose $D$ (in $\\mathrm{mg}$) and clearance $CL$ (in $\\mathrm{L/h}$), the exposure is $X = D/CL$ with units $\\mathrm{mg \\cdot h/L}$.\n- Clearance distribution: interindividual variability in clearance is described by a lognormal distribution, $CL \\sim \\mathrm{LogNormal}(\\mu, \\sigma^{2})$, where the median clearance is $\\mathrm{median}(CL) = \\exp(\\mu)$. The coefficient of variation (as a decimal) is $\\mathrm{CV}$, and for a lognormal distribution this implies $\\sigma = \\sqrt{\\ln(1 + \\mathrm{CV}^{2})}$ and $\\mu = \\ln(\\mathrm{median}(CL))$.\n- Efficacy model: an $E_{\\max}$ function of exposure, $E(X) = E_{0} + E_{\\max}\\,\\dfrac{X}{EC_{50} + X}$, where $E_{0}$ is the baseline, $E_{\\max}$ the maximal incremental effect, and $EC_{50}$ the exposure producing half of maximal incremental effect.\n- Safety model: the probability of an adverse event at exposure $X$ follows a logistic function, $p_{\\mathrm{AE}}(X) = \\dfrac{1}{1 + \\exp\\!\\big(-(\\alpha + \\beta X)\\big)}$.\n\nDecision rule to select two Phase III doses from a fixed candidate grid:\n- Let the candidate dose grid be $D \\in \\{5, 10, 15, \\dots, 200\\}$ in $\\mathrm{mg}$.\n- For each candidate dose $D$, simulate $N$ exposures by sampling $CL$ from the specified lognormal distribution, compute exposures $X = D/CL$, and then compute the empirical means $\\bar{E}(D) = \\mathbb{E}[E(X)]$ and $\\bar{p}_{\\mathrm{AE}}(D) = \\mathbb{E}[p_{\\mathrm{AE}}(X)]$ using Monte Carlo averaging.\n- Define the acceptable safety bound $p_{\\max}$ (a decimal, not a percentage). A dose $D$ is feasible if $\\bar{p}_{\\mathrm{AE}}(D) \\le p_{\\max}$.\n- High dose $D_{2}$: among feasible doses, choose $D_{2}$ that maximizes $\\bar{E}(D)$; in case of ties within a numerical tolerance of $10^{-9}$, choose the smallest $D$ attaining that maximum.\n- Low dose $D_{1}$: among feasible doses with $D \\le D_{2}$, choose the smallest dose such that $\\bar{E}(D) \\ge f \\cdot \\bar{E}(D_{2})$, where $f \\in (0,1)$ is the target efficacy fraction. If no such dose exists with $D \\le D_{2}$, set $D_{1} = D_{2}$.\n- Infeasibility: if no dose is feasible, return the sentinel pair $[-1.0, -1.0]$ (in $\\mathrm{mg}$).\n\nAll simulations must use the Law of Large Numbers to approximate expectations by sample means. The program must set the random seed as provided to ensure reproducibility.\n\nAngle units are not applicable. All reported dose values must be in $\\mathrm{mg}$ as plain numeric values without unit strings. Do not include percentage signs anywhere; all risk bounds and fractions must be decimals.\n\nTest suite:\nFor each test case, you are given $(E_{0}, E_{\\max}, EC_{50}, \\mathrm{median}(CL), \\mathrm{CV}, \\alpha, \\beta, p_{\\max}, f, N, \\mathrm{seed})$. Use the candidate dose grid $D \\in \\{5, 10, \\dots, 200\\}$ in $\\mathrm{mg}$.\n\n- Case A (typical benefit–risk):\n  - $E_{0} = 0.1$, $E_{\\max} = 0.6$, $EC_{50} = 15$\n  - $\\mathrm{median}(CL) = 5$ $\\mathrm{L/h}$, $\\mathrm{CV} = 0.5$\n  - $\\alpha = -3$, $\\beta = 0.1$\n  - $p_{\\max} = 0.2$, $f = 0.8$\n  - $N = 20000$, $\\mathrm{seed} = 13$\n- Case B (higher efficacy need with moderate safety):\n  - $E_{0} = 0.05$, $E_{\\max} = 0.5$, $EC_{50} = 20$\n  - $\\mathrm{median}(CL) = 3$ $\\mathrm{L/h}$, $\\mathrm{CV} = 0.4$\n  - $\\alpha = -4$, $\\beta = 0.12$\n  - $p_{\\max} = 0.25$, $f = 0.75$\n  - $N = 20000$, $\\mathrm{seed} = 42$\n- Case C (tight safety constraint with high variability):\n  - $E_{0} = 0.1$, $E_{\\max} = 0.4$, $EC_{50} = 10$\n  - $\\mathrm{median}(CL) = 5$ $\\mathrm{L/h}$, $\\mathrm{CV} = 0.8$\n  - $\\alpha = -3.5$, $\\beta = 0.18$\n  - $p_{\\max} = 0.1$, $f = 0.85$\n  - $N = 20000$, $\\mathrm{seed} = 7$\n- Case D (infeasible safety):\n  - $E_{0} = 0.2$, $E_{\\max} = 0.3$, $EC_{50} = 25$\n  - $\\mathrm{median}(CL) = 10$ $\\mathrm{L/h}$, $\\mathrm{CV} = 0.5$\n  - $\\alpha = -2$, $\\beta = 0.2$\n  - $p_{\\max} = 0.02$, $f = 0.8$\n  - $N = 20000$, $\\mathrm{seed} = 99$\n\nYour task:\n- Implement a program that carries out the simulation and selection as specified above for each test case.\n- The final output must be a single line containing a list of length $4$, where each element is a pair $[D_{1}, D_{2}]$ (both in $\\mathrm{mg}$ as floats) for the corresponding test case in the given order. Use the exact formatting of a comma-separated list enclosed in square brackets, with the inner pairs also enclosed in square brackets, for example: $[[10.0,20.0],[\\dots],[\\dots],[\\dots]]$. If a case is infeasible, output $[-1.0,-1.0]$ for that case.",
            "solution": "The user has provided a valid problem statement grounded in the principles of clinical pharmacometrics. The task is to select two Phase III doses, a high dose $D_2$ and a low dose $D_1$, from a candidate grid by simulating exposure-response profiles and applying a set of formalized decision rules.\n\nThe solution is implemented by following these steps for each test case.\n\n1.  **Model and Simulation Setup**\n    The problem is defined by a set of pharmacometric models. Drug exposure, $X$, is linearly related to the dose $D$ and clearance $CL$ by $X = D/CL$. The interindividual variability in clearance is modeled by a lognormal distribution, $CL \\sim \\mathrm{LogNormal}(\\mu, \\sigma^{2})$. The parameters $\\mu$ and $\\sigma$ of the associated normal distribution for $\\ln(CL)$ are derived from the given median clearance, $\\mathrm{median}(CL)$, and coefficient of variation, $\\mathrm{CV}$:\n    $$ \\mu = \\ln(\\mathrm{median}(CL)) $$\n    $$ \\sigma = \\sqrt{\\ln(1 + \\mathrm{CV}^{2})} $$\n    The efficacy response, $E(X)$, is an $E_{\\max}$ function of exposure:\n    $$ E(X) = E_{0} + E_{\\max}\\,\\dfrac{X}{EC_{50} + X} $$\n    The probability of a specific adverse event, $p_{\\mathrm{AE}}(X)$, is a logistic function of exposure:\n    $$ p_{\\mathrm{AE}}(X) = \\dfrac{1}{1 + \\exp\\!\\big(-(\\alpha + \\beta X)\\big)} $$\n    The candidate dose grid is defined as the set of integer doses $D \\in \\{5, 10, 15, \\dots, 200\\}$ $\\mathrm{mg}$.\n\n2.  **Monte Carlo Expectation Approximation**\n    For each test case, the random seed is set to the provided value to ensure reproducibility. A large number of clearance values, $N$, are sampled from the specified lognormal distribution: $\\{cl_1, cl_2, \\dots, cl_N\\}$.\n    Then, for each candidate dose $D$ in the grid, the following procedure is executed:\n    *   A vector of $N$ exposures is calculated: $x_i = D/cl_i$ for $i=1, \\dots, N$.\n    *   Using this exposure vector, corresponding vectors for efficacy and adverse event probability are computed using the $E(X)$ and $p_{\\mathrm{AE}}(X)$ functions.\n    *   By the Law of Large Numbers, the expected efficacy $\\bar{E}(D)$ and expected adverse event probability $\\bar{p}_{\\mathrm{AE}}(D)$ are approximated by their respective sample means:\n        $$ \\bar{E}(D) = \\mathbb{E}[E(X)] \\approx \\frac{1}{N} \\sum_{i=1}^{N} E(x_i) $$\n        $$ \\bar{p}_{\\mathrm{AE}}(D) = \\mathbb{E}[p_{\\mathrm{AE}}(X)] \\approx \\frac{1}{N} \\sum_{i=1}^{N} p_{\\mathrm{AE}}(x_i) $$\n    The resulting pair $(\\bar{E}(D), \\bar{p}_{\\mathrm{AE}}(D))$ is stored for each candidate dose $D$.\n\n3.  **Application of Decision Rules**\n    After computing the expected outcomes for all candidate doses, the following rules are applied to select $D_1$ and $D_2$:\n\n    *   **Feasibility Assessment**: A dose $D$ is deemed feasible if its expected adverse event probability does not exceed a predefined maximum acceptable probability, $p_{\\max}$. That is, $\\bar{p}_{\\mathrm{AE}}(D) \\le p_{\\max}$. All doses that do not meet this criterion are removed from consideration. If no doses are feasible, the process terminates for the current test case, and the sentinel pair $[-1.0, -1.0]$ is returned.\n\n    *   **High Dose ($D_2$) Selection**: Among the set of feasible doses, the one that provides the maximum expected efficacy is identified. Let this maximum efficacy be $\\bar{E}_{\\max} = \\max \\{ \\bar{E}(D) \\mid D \\text{ is feasible} \\}$. To account for numerical precision, any feasible dose $D$ with an efficacy $\\bar{E}(D) \\ge \\bar{E}_{\\max} - 10^{-9}$ is considered a candidate for the high dose. From this set of candidates, the one with the smallest dose value is selected as $D_2$. This rule selects for the most potent dose at the plateau of the dose-response curve while being conservative on dose.\n\n    *   **Low Dose ($D_1$) Selection**: The low dose $D_1$ is intended to provide a substantial fraction, $f$, of the efficacy achieved by $D_2$. The target efficacy is defined as $E_{\\text{target}} = f \\cdot \\bar{E}(D_2)$, where $\\bar{E}(D_2)$ is the expected efficacy of the selected high dose. The search for $D_1$ is restricted to the set of feasible doses $D$ such that $D \\le D_2$. From this subset, the smallest dose $D$ that satisfies $\\bar{E}(D) \\ge E_{\\text{target}}$ is chosen as $D_1$. If no dose in this subset meets the target efficacy, it implies that even the lowest doses providing meaningful efficacy are close to $D_2$. In this specific scenario, the low dose is set to be equal to the high dose, $D_1 = D_2$.\n\nThis entire procedure is encapsulated in a program that processes each test case and aggregates the resulting $[D_1, D_2]$ pairs into a final list for output. A sample implementation is provided below.\n\n```python\nimport numpy as np\n\ndef select_doses(params):\n    \"\"\"\n    Performs Monte Carlo simulation and applies decision rules for a single test case.\n\n    Args:\n        params (tuple): A tuple containing all model and simulation parameters.\n\n    Returns:\n        list: A list [d1, d2] containing the selected low and high doses as floats.\n              Returns [-1.0, -1.0] if no feasible dose is found.\n    \"\"\"\n    E0, Emax, EC50, med_CL, CV, alpha, beta, p_max, f, N, seed = params\n    \n    np.random.seed(seed)\n    \n    dose_grid = np.arange(5, 201, 5)\n    \n    mu_log_cl = np.log(med_CL)\n    sigma_log_cl = np.sqrt(np.log(1 + CV**2))\n    \n    cl_samples = np.random.lognormal(mu_log_cl, sigma_log_cl, N)\n    \n    metrics = {}\n    \n    for d in dose_grid:\n        x_samples = d / cl_samples\n        e_samples = E0 + Emax * x_samples / (EC50 + x_samples)\n        p_ae_samples = 1 / (1 + np.exp(-(alpha + beta * x_samples)))\n        e_bar = np.mean(e_samples)\n        p_ae_bar = np.mean(p_ae_samples)\n        metrics[d] = (e_bar, p_ae_bar)\n        \n    feasible_doses = {d: v for d, v in metrics.items() if v[1] = p_max}\n    \n    if not feasible_doses:\n        return [-1.0, -1.0]\n\n    max_e_bar = max(v[0] for v in feasible_doses.values())\n    \n    d2_candidates = [d for d, v in feasible_doses.items() if v[0] >= max_e_bar - 1e-9]\n    d2 = min(d2_candidates)\n\n    e_bar_at_d2 = feasible_doses[d2][0]\n    e_target = f * e_bar_at_d2\n    \n    d1_candidates = [\n        d for d, v in feasible_doses.items() \n        if d = d2 and v[0] >= e_target\n    ]\n    \n    if not d1_candidates:\n        d1 = d2\n    else:\n        d1 = min(d1_candidates)\n        \n    return [float(d1), float(d2)]\n```",
            "answer": "[[70.0,90.0],[80.0,120.0],[45.0,60.0],[-1.0,-1.0]]"
        }
    ]
}